Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 5/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7982398 | 0.93 | UTS2R (0.35) | PTGER1CETPGAALMNAGPR55 | |
| SCHEMBL7986061 | 0.91 | PTGER1 (0.35) | PTGER1CYP2C9HTR2CSLC6A4CETP | |
| SCHEMBL7986054 | 0.91 | PTGER1 (0.34) | PTGER1CYP2C9HTR2CSLC6A4CETP | |
| SCHEMBL7982389 | 0.90 | CETP (0.34) | PTGER1CETPGAALMNA | |
| SCHEMBL7572801 | 0.83 | F2 (0.38) | PTGER1CETPGAAGPR55 | |
| SCHEMBL8058096 | 0.83 | CETP (0.38) | PTGER1CETPGAAGPR55 | |
| SCHEMBL8047891 | 0.83 | GAA (0.36) | PTGER1CETPGAALMNAGPR55 | |
| SCHEMBL7515830 | 0.83 | GAA (0.36) | PTGER1CETPGAALMNA | |
| SCHEMBL7982400 | 0.82 | F2 (0.39) | PTGER1CETPGPR55 | |
| SCHEMBL7209116 | 0.82 | GAA (0.38) | PTGER1CETPGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6297241-B1 | TREATMENT OF DISORDERS WHICH ARE RESPONSIVE TO THE OPENING OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS. | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | disclosed |